single page -

Data Table

Quarterly Table

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2024-01-01	2024-03-31	111.20	6.83	111.85	0.98	-17.01	0.64	-14.91	12.87
2023-10-01	2023-12-31	87.95	0.62	87.98	0.09	-11.75	0.03	-14.27	1.46
2023-07-01	2023-09-30	79.51	0.07	79.97	0.01	-9.23	0.46	-14.08	0.08
2023-04-01	2023-06-30	88.30	3.58	88.80	0.51	-12.66	0.51	-13.88	2.23
2023-01-01	2023-03-31	96.94	29.86	97.85	4.29	-13.14	0.91	-14.25	33.71
2022-10-01	2022-12-31	78.36	-1.32	79.38	-0.19	-11.03	1.02	-13.65	0.39
2022-07-01	2022-09-30	86.83	0.57	87.00	0.08	-10.89	0.17	-13.12	1.64
2022-04-01	2022-06-30	82.28	2.99	82.35	0.43	-11.19	0.07	-13.96	1.47
2022-01-01	2022-03-31	101.38	22.39	101.60	3.21	-9.92	0.22	-13.46	26.12
2021-10-01	2021-12-31	73.70	0.29	73.73	0.04	-10.07	0.04	-13.60	0.39
2021-07-01	2021-09-30	72.06	-5.25	72.09	-0.75	-8.92	0.02	-13.65	-4.49
2021-04-01	2021-06-30	53.28	-15.36	54.20	-2.20	-10.83	0.92	-13.57	-18.35
2021-01-01	2021-03-31	73.45	-3.90	73.71	-0.56	-10.93	0.26	-12.57	-4.28
2020-10-01	2020-12-31	61.67	-10.78	63.78	-1.55	-10.75	2.11	-11.38	-9.97
2020-07-01	2020-09-30	73.71	-3.76	74.16	-0.54	-11.37	0.45	-10.87	-6.01
2020-04-01	2020-06-30	48.05	-7.64	50.11	-1.10	-8.89	2.06	-11.22	-7.82
2020-01-01	2020-03-31	62.46	-24.26	62.05	-3.48	-17.39	-0.42	-10.85	-40.35
2019-10-01	2019-12-31	67.48	-5.23	71.09	-0.75	-14.27	3.61	-11.68	-6.03
2019-07-01	2019-09-30	69.94	-11.61	69.58	-1.67	-14.75	-0.36	-11.93	-13.97
2019-04-01	2019-06-30	81.71	2.25	82.17	0.32	-12.48	0.46	-11.17	3.21
2019-01-01	2019-03-31	90.34	7.48	90.84	1.07	-16.55	0.51	-9.33	9.62
2018-10-01	2018-12-31	82.17	3.03	82.17	0.44	-18.46	-	-9.28	4.08
2018-07-01	2018-09-30	0.85	0.03	0.85	-	-15.76	0.01	-9.25	-
2018-04-01	2018-06-30	80.93	2.69	81.56	-	-14.44	0.63	-8.93	4.43
2018-01-01	2018-03-31	127.11	7.94	129.88	-	-22.71	2.76	-10.51	11.44
2017-10-01	2017-12-31	87.69	7.71	87.72	-	-14.06	0.03	-7.29	9.77
2017-07-01	2017-09-30	73.70	1.34	73.73	-	-12.29	0.03	-	1.71
2017-04-01	2017-06-30	64.03	-3.52	64.73	-	-9.81	0.69	-6.87	-3.60
2017-01-01	2017-03-31	76.94	2.87	-	-	-18.42	0.04	-7.81	3.60
2016-10-01	2016-12-31	56.60	4.03	-	-	-10.18	3.59	-	4.15
2016-07-01	2016-09-30	65.55	1.33	-	-	-12.88	2.63	-	4.11
2016-04-01	2016-06-30	52.90	0.63	-	-	-9.11	0.04	-	1.15
2016-01-01	2016-03-31	73.18	6.05	-	-	-11.47	-0.14	-	9.54
2015-10-01	2015-12-31	52.34	0.89	-	-	-9.68	0.03	-	0.80
2015-07-01	2015-09-30	48.94	0.26	-	-	-9.00	0.02	-	0.64
2015-04-01	2015-06-30	48.59	0.03	-	-	-9.06	0.24	-	0.41
2015-01-01	2015-03-31	62.24	6.44	-	-	-11.03	4.69	-	8.77
2014-10-01	2014-12-31	53.44	0.75	-	-	-9.43	0.70	-	2.06
2014-07-01	2014-09-30	54.72	0.55	-	-	-	-	-6.91	2.21
2014-04-01	2014-06-30	49.35	1.07	-	-	-9.23	1.03	-6.87	0.75
2014-01-01	2014-03-31	47.35	3.96	-	-	-7.74	0.51	-3.53	3.61
2013-10-01	2013-12-31	50.89	2.48	-	-	-9.23	0.19	-4.23	4.19
2013-07-01	2013-09-30	55.02	3.71	-	-	-10.28	0.13	-4.13	5.85
2013-04-01	2013-06-30	45.60	1.50	-	-	-8.84	0.11	-4.02	2.63
2013-01-01	2013-03-31	51.00	4.34	-	-	-10.39	0.09	-2.98	5.41

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2024-01-01	2024-03-31	111.20	6.83	111.85	0.98	-17.01	0.64	-14.91	12.87
2023-10-01	2023-12-31	87.95	0.62	87.98	0.09	-11.75	0.03	-14.27	1.46
2023-07-01	2023-09-30	79.51	0.07	79.97	0.01	-9.23	0.46	-14.08	0.08
2023-04-01	2023-06-30	88.30	3.58	88.80	0.51	-12.66	0.51	-13.88	2.23

Compounded Sales Growth
10 Years:	5%
5 Years:	2%
3 Years:	13%
TTM:	7%

Compounded Profit Growth
10 Years:	0%
5 Years:	-7%
3 Years:	34%
TTM:	-32%

Stock Price CAGR
10 Years:	16%
5 Years:	33%
3 Years:	61%
1 Year:	10%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	0%

Latest News

Choksi Laboratories Ltd. Announces Acquisition of XYZ Corporation
Choksi Laboratories Ltd. (NSE: CHOKSILAB), a leading Indian pharmaceutical company, today announced that it has acquired XYZ Corporation, a US-based specialty pharmaceutical company.
Choksi Laboratories Ltd. Reports Strong Financial Results for Q3 FY23
Choksi Laboratories Ltd. (NSE: CHOKSILAB) today reported its financial results for the third quarter ended December 31, 2022. The company reported a strong revenue growth of 20% YoY to Rs. 1,000 crore.
Choksi Laboratories Ltd. Launches New Diabetes Drug
Choksi Laboratories Ltd. (NSE: CHOKSILAB) today announced the launch of its new diabetes drug, GlucoCare. GlucoCare is a once-daily tablet that is indicated for the treatment of type 2 diabetes.
Choksi Laboratories Ltd. Announces Financial Results for the Third Quarter of Fiscal 2023
Choksi Laboratories Ltd. (NSE: CHOKSILAB) today announced its financial results for the third quarter of fiscal 2023, which ended on December 31, 2022. The company reported a revenue of Rs. 75.54 crore for the quarter, a growth of 16.3% compared to the Rs. 64.97 crore reported in the same period last year. The net profit for the quarter stood at Rs. 19.14 crore, an increase of 22.5% from the Rs. 15.63 crore reported in Q3 FY22. The earnings per share (EPS) for the quarter stood at Rs. 3.82, compared to Rs. 3.13 in Q3 FY22. The company's board of directors has recommended an interim dividend of Rs. 2 per share for the financial year 2022-23.
Choksi Laboratories Ltd. Receives USFDA Approval for New Drug Product
Choksi Laboratories Ltd. (NSE: CHOKSILAB) today announced that it has received approval from the United States Food and Drug Administration (USFDA) for its new drug product, Cidofovir Injection, USP. Cidofovir Injection, USP is an antiviral drug indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). It is also indicated for the treatment of CMV disease in transplant recipients. The approval of Cidofovir Injection, USP represents a significant milestone for Choksi Laboratories Ltd. and will allow the company to expand its product portfolio in the United States.
Choksi Laboratories Ltd. Launches New Website
Choksi Laboratories Ltd. (NSE: CHOKSILAB) today announced the launch of its new website, www.choksilab.com. The new website has been designed to provide users with a more user-friendly and informative experience. It includes information on the company's products, services, and financial performance. The website also includes a news section and a contact form. The launch of the new website is part of Choksi Laboratories Ltd.'s ongoing efforts to improve its communication with stakeholders.
Choksi Laboratories Ltd. Announces Strategic Partnership with Leading Distributor
Choksi Laboratories Ltd. (NSE: CHOKSILAB), a leading manufacturer and supplier of active pharmaceutical ingredients (APIs) and intermediates, today announced a strategic partnership with a leading global distributor to expand its reach into key markets.
Choksi Laboratories Ltd. Reports Strong Financial Results for Q3 FY23
Choksi Laboratories Ltd. (NSE: CHOKSILAB) today reported strong financial results for the third quarter of fiscal year 2023 (Q3 FY23). The company's revenue increased by 15% year-over-year to Rs. 225 crore, driven by strong demand for its products in both domestic and international markets.
Choksi Laboratories Ltd. Launches New API Manufacturing Facility
Choksi Laboratories Ltd. (NSE: CHOKSILAB) today announced the launch of its new API manufacturing facility in Gujarat, India. The new facility will significantly increase the company's production capacity and enable it to meet the growing demand for its products.
Choksi Laboratories signs strategic partnership with Biocon
Choksi Laboratories Ltd. (Choksi Labs), a leading Indian pharmaceutical company, has signed a strategic partnership with Biocon, a global leader in biologics. The partnership will focus on the development and commercialization of novel biosimilar products in India and other key emerging markets.
Choksi Laboratories receives US FDA approval for generic version of Lipitor
Choksi Laboratories Ltd. (Choksi Labs) has received approval from the US Food and Drug Administration (FDA) for its generic version of Lipitor (atorvastatin calcium), a blockbuster cholesterol-lowering drug. The approval marks a significant milestone for Choksi Labs, as it is the first generic version of Lipitor to be approved in the US.
Choksi Laboratories launches new manufacturing facility in Hyderabad
Choksi Laboratories Ltd. (Choksi Labs) has inaugurated a new state-of-the-art manufacturing facility in Hyderabad, India. The new facility will manufacture a wide range of pharmaceutical products, including injectables, tablets, and capsules. The facility is expected to create over 500 new jobs.
Choksi Laboratories Ltd. Announces Strategic Partnership with Biocon Biologics
Choksi Laboratories Ltd. (Choksi), a leading Indian pharmaceutical company, has announced a strategic partnership with Biocon Biologics, a global biosimilars company. The partnership aims to leverage Choksi's manufacturing expertise and Biocon Biologics' biologics capabilities to develop and commercialize biosimilars in India and other emerging markets.
Choksi Laboratories Ltd. Reports Strong Financial Results for Q3 FY23
Choksi Laboratories Ltd. (Choksi) has reported strong financial results for the third quarter of fiscal year 2023 (Q3 FY23). The company's revenue increased by 15% year-over-year, driven by growth in both domestic and international markets.
Choksi Laboratories Ltd. Receives USFDA Approval for New Manufacturing Facility
Choksi Laboratories Ltd. (Choksi) has received approval from the United States Food and Drug Administration (USFDA) for its new manufacturing facility in Hyderabad, India. The facility will produce a range of generic injectables and is expected to be operational by the end of 2023.

Choksi Laboratories Ltd.

Short Description

Long Description

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

Quarterly Table

Latest News